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doi:10.1016/j.kjms.2012.04.032Abstract Liver stiffness measurement (LSM) is a noninvasive method for the diagnosis of
hepatic fibrosis. The aim of this study was to evaluate the effects of hepatitis activity and anti-
viral therapy on LSM in cirrhotic patients. Consecutive patients with compensated hepatic
cirrhosis were enrolled for LSM. The medical records of hepatitis activity and antiviral therapy
before enrollment were reviewed. Patients were stratified into inactive, fluctuating,
and active groups by serial change of alanine transaminase level. For chronic hepatitis C,
patients were stratified into sustained virological response (SVR) and non-SVR (NSVR) by effect
of antiviral treatment. LSM results were compared among different groups. A total of 163
patients (mean age Z 57.2  11.0 years) were enrolled. The median (range) LSM values were
9.6 (4.2e20.6), 10.25 (3.9e49.6), and 15.75 (4.8e61.5) kPa in the inactive, fluctuating,
and active groups, respectively. Patients in the active group had significantly higher
LSM values. For chronic hepatitis C, median (range) LSM values were 16.6 (8.1e61.5), 22.9
(11.1e37.4), and 11.2 (3.9e27.0) kPa in patients without antiviral therapy, in NSVR, and
in SVR groups, respectively. Patients with SVR had significantly lower LSM values. For
chronic hepatitis B, median (range) LSM values were 11.8 (5.1e46.6), 16.85 (4.2e48), and
10.6 (4.3e46.4 kPa) kPa in patients without oral nucleos(t)ide analogue (NA) therapy, with
NA< 12, andS12months, respectively. Therewas a significantly lower LSM value in patientswith
NAtherapyS12months. Therewere lowLSMvalues incirrhoticpatientswithouthepatitis activity,
as well as with SVR in chronic hepatitis C and long-term NA therapy in chronic hepatitis B.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.epato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital,
3, Kaohsiung City, Taiwan.
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the completion of standard treatment. US with a reliableTable 1 Demographics and clinical characteristics of the
enrolled patients.
Groups n Z 163 (%)
Age (y) 57.2  11.0
Sex
Male 93 (57.1)
Female 70 (42.9)
BMI (kg/m2) 25.6  3.7
Histology cirrhosis 51 (31.3)
Etiology
Hepatitis B virus 90 (55.2)
Hepatitis C virus 47 (28.8)
Hepatitis B and C virus 18 (11.0)
Others 8 (5.0)
Platelet count (109/L) 125.1  52.3
Prothrombin time (INR) 1.06  0.10
AST (UI/L) 47.1  35.6
ALT (UI/L) 49.4  50.4
Albumin (g/dL) 4.2  0.4
Total bilirubin (mg/dL) 1.1  0.5
Fatty change
No/mild/
moderate/severe
126 (77.3)/27
(16.6)/1 0 (6.1)/0 (0)
Splenomegaly
Yes 90 (55.2)
No 73 (44.8)
Liver stiffness (range, kPa) 12 (3.9e61.5)
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; BMI Z body mass index; INR Z international
normalized ratio.Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)
infections are the major causes of chronic liver disease.
Cirrhosis is a late stage of hepatic fibrosis, which occurs in
response to chronic liver injury. Therefore, hepatic fibrosis
and cirrhosis evaluation is highly important in the
management of patients with chronic viral hepatitis [1,2].
Liver biopsy is the gold standard for the diagnosis of hepatic
cirrhosis. To avoid patient discomfort and possible fatal
complications of liver biopsy, noninvasive measures are
valuable in the diagnosis and monitoring of the severity of
chronic liver disease.
Liver stiffness measurement (LSM) by transient elastog-
raphy is a noninvasive, painless, rapid, and objective
method for the evaluation of fibrosis or cirrhosis [3].
Systemic reviews and meta-analyses have demonstrated
the high sensitivity and specificity of LSM in the diagnosis of
hepatic cirrhosis [4e7]. LSM, however, was affected by not
only inherent hepatic disease, but also hemodynamic
change and comorbidities [8, 9]. Studies have suggested
that liver stiffness value has been shown to increase with
increasing necroinflammatory scores at histology and in
biochemical flares of hepatitis [10e12]. For patients with
chronic HBV or HCV infection, effective antiviral therapy
also decreased liver stiffness in long-term follow-up studies
[13,14]. The purpose of this study was to evaluate the
effects of hepatitis activity and antiviral therapy on LSM in
patients with hepatic cirrhosis.
Patients and methods
Between November 2008 and December 2009, consecutive
patients with compensated hepatic cirrhosis by ultraso-
nography (US) and/or histology were enrolled. The defini-
tion of compensated cirrhosis included patients with liver
function reserve in ChildePugh A without histories of
hepatic encephalopathy, ascites, and varices bleeding.
Patients with implanted pacemakers or who were pregnant
were excluded. The study was approved by the ethics
committee in this hospital and conformed to the Helsinki
Declaration. All patients signed an informed consent form
before enrollment.
We reviewed all medical records of the enrolled patients
in the 2-year period before enrollment. Baseline clinical
characteristics and demographics including age, sex, body
mass index, etiology of cirrhosis, platelet count, and
prothrombin time, as well as aspartate aminotransferase,
alanine aminotransferase (ALT), albumin, and total bili-
rubin levels were recorded. At least three ALT data were
recorded for each patient. Normal ALT level was defined as
<40 IU/L. A patient with persistent normal ALT level was
defined as inactive activity of hepatitis. Those with episodic
ALT elevation and persistent abnormal ALT level were
defined as fluctuating and active activity of hepatitis,
respectively. The treatments of chronic HCV and HBV
infection and their effects were recorded. For chronic
hepatitis C patients under antiviral therapy, sustained
virological response (SVR) was defined as undetectable
HCV-RNA at 6 months after completion of standard treat-
ment. On the other hand, non-sustained virologicalresponse (NSVR) was detectable HCV-RNA at 6 months after
scoring system was used in the diagnosis of hepatic cirrhosis
and evaluation of fatty change according to the criteria
proposed by the Asian Pacific Association for Study of the
Liver [15,16]. Ultrasonographic splenomegaly was defined
as spleen size index >20 cm2 [15].
LSM evaluation
LSMwasperformedwith a FibroScan system (Echosens, Paris,
France), which is a device based on the one-dimensional
transient elastography technique. LSM was performed
according to the manufacturer’s instructions. Details of the
LSM technique have been described in a previously published
paper [13]. The LSM result was reliable only when 10
successful shots, a success rate of at least 65%, and an
interquartile range lower than 30% were obtained. LSM
results were compared among different groups.
Statistical analysis
LSM results were expressed as a median value with an
interquartile range in kilopascal (kPa). Other results were
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uous data and as frequencies or percentages for categorical
data. Differences between subgroups were analyzed using
the KruskaleWallis test and ManneWhitney rank sum test
when appropriate. Chi-square test was used for categorical
variables. Statistical significance was taken as p < 0.05. All
statistical analyses were performed with SPSS, version 17
(SPSS, Inc., Chicago, IL, USA).Results
Patients
A total of 163 patients, comprising 93 men and 70 women,
with a mean age of 57.2  11.0 years, were enrolled. There
were 90 (55.2%) patients with positive hepatitis B surface
antigen, 47 (28.8%) patients with positive antibody to
hepatitis C virus (anti-HCV), and 18 (11.0%) patients posi-
tive for both hepatitis B surface antigen and anti-HCV.
Hepatic cirrhosis was diagnosed with both histology and US
in 51 (31.3%) patients. Thrombocytopenia (platelet count
<150  109/L) was diagnosed in 111 (68.1%) patients.
Ultrasonographic splenomegaly was diagnosed in 90 (55.2%)
patients. The median LSM value was 12 kPa (range
3.9e61.5 kPa). Table 1 shows the demographics and base-
line clinical characteristics of the enrolled patients.Table 2 Demographics and clinical characteristics of patients s
term biochemical activity of hepatitis.
Groups Inactive
n Z 21 (%)
Age (y) 62.5  11.8 5
Sex
Male 11 (52.4) 4
Female 10 (47.6) 2
BMI (kg/m2) 25.0  3.2 2
Etiology
Hepatitis B virus 10 (47.6) 3
Hepatitis C virus 2 (9.5) 2
Hepatitis B and C virus 6 (28.6) 6
Platelet count (109/L)
<150 11 (52.4) 4
S150 10 (47.6) 2
Prothrombin time (INR) 1.03  0.04 1
AST (UI/L) 28.0  7.6 3
ALT (UI/L) 21.3  4.7 3
Albumin (g/dL) 4.4  0.4 4
Total bilirubin (mg/dL) 1.3  0.6 1
Fatty change
No/mild/moderate/severe 17 (81.0)/3 (14.3) 5
1 (4.8)/0 (0) 2
Liver stiffness (range, kPa) 9.6 (4.2e20.6) 1
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;Liver stiffness and ALT level
According to the activity of hepatitis in the given definition,
the patients were grouped into inactive, fluctuating, and
active groups. Table 2 shows the demographics and clinical
characteristics of these patients by group. There were no
statistically significant differences among the three groups in
terms of sex, body mass index, etiology of cirrhosis, patients
with thrombocytopenia, prothrombin time, albumin, total
bilirubin, or severity of fatty change. The patients in the
active group were younger and had higher aminotransferase
and ALT levels. The median LSM value was 9.6 kPa (range
4.2e20.6 kPa), 10.3 kPa (range 3.9e49.6 kPa), and 15.8 kPa
(range 4.8e61.5 kPa) for the inactive, fluctuating, and active
groups, respectively. There was a significant difference in
LSM results among the three groups (p < 0.001). There were
significant differences between inactive and active groups
(p < 0.001), and also significant differences between fluc-
tuating and active groups (pZ 0.001). Patients in the active
group had a significantly higher LSM value than those in the
other two groups (Fig. 1).
Liver stiffness and patients with chronic HCV
Forty-seven (28.8%) patients had a history of chronic HCV
infection. The standard treatment of chronic HCV infection is
interferon-based regimens. According to antiviral treatmenttratified into inactive, fluctuating, and active groups by long-
Fluctuating
n Z 70 (%)
Active
n Z 72 (%)
p
8.7  10.1 54.3  11.0 0.003
4 (62.9) 38 (52.8) 0.430
6 (37.1) 34 (47.2)
5.1  3.5 26.3  4.0 0.096
9 (55.7) 41 (56.9) 0.583
1 (30.0) 24 (33.3) 0.917
(8.6) 6 (8.3)
6 (65.7) 54 (75.0) 0.126
4 (34.3) 18 (25.0)
.07  0.14 1.07  0.06 0.553
6.1  15.3 63.3  46.5 <0.001
2.59  21.6 73.9  65.0 <0.001
.2  0.4 4.1  0.4 0.103
.1  0.5 1.2  0.5 0.257
9 (84.3)/9 (12.9) 50 (69.4)/15 (20.8) 0.263
(2.9)/0 (0) 7 (9.7)/0 (0)
0.3 (3.9e49.6) 15.8 (4.8e61.5) <0.001
BMI Z body mass index; INR Z international normalized ratio.
Figure 1. Liver stiffness values stratified by hepatitis
activity in patients with compensated cirrhosis. Error bars
indicate the smallest and the largest values. The boundary of
boxes closest to 0 indicates the 25th percentile, the line within
boxes shows the median, and the boundary of boxes furthest
from 0 indicates the 75th percentile. The median liver stiffness
measurement (LSM) values were 9.6 kPa (range 4.2e20.6 kPa)
in the inactive group, 10.3 kPa (range 3.9e49.6 kPa) in the
fluctuating group, and 15.8 kPa (range 4.8e61.5 kPa) in the
active group.
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groups: 21 patients without antiviral therapy, 14 patients
receiving antiviral therapy with SVR, and 12 patients
receiving antiviral therapy with NSVR. For antiviral therapy,
all patients received combined pegylated interferon with
ribavirin treatment for 13e48 weeks. The interval between
establishment of SVR and LSM ranged from 1.2 to 8.5 years
(mean  SD, 3.6  2.5 years). Table 3 shows the demo-
graphics and clinical characteristics of patients of all three
groups. The median LSM value was 16.6 kPa (range
8.1e61.5 kPa), 22.9 kPa (range 11.1e37.4 kPa), and 11.2 kPa
(range 3.9e27.0 kPa) in patients without antiviral therapy,
patients in the NSVR group, and patients in the SVR group,
respectively. There were significant differences (pZ 0.003)
among the three groups. Patients with SVR had significantly
lower LSM values than those in the NSVR group and those
without antiviral therapy (p < 0.001 and p Z 0.015,
respectively) (Fig. 2).
Liver stiffness and patients with chronic HBV
Ninety (55.2%) patients had chronic HBV infection. One
patient was excluded due to treatment with pegylatedinterferon. The remaining 89 patients were divided into
three groups: 43 patients without antiviral therapy, 13
patients with oral nucleoside/nucleotide analogue (NA)
therapy for less than 12 months, and 33 patients with oral
NA for more than 12 months. There were 42 patients with
monotherapy, including entecavir, adefovir, lamivudine,
and telbivudine. Four patients received combined lam-
ivudine or telbivudine with adefovir therapy. For patients
with NA therapy for more than 12 months, the interval
between the beginning of treatment and LSM ranged from
1.0 to 5.0 years (mean  SD, 2.9  1.2 years). Table 4 shows
the demographics and clinical characteristics of patients in
these three groups. The median LSM value was 11.8 kPa
(range 5.1e46.6 kPa), 16.9 kPa (range 4.2e48 kPa), and
10.6 kPa (range 4.3e46.4 kPa) in patients without antiviral
therapy, those with NA therapy less than 12 months, and
those with NA therapy more than 12 months, respectively.
There were significant differences (p Z 0.009) among the
three groups. There was a significant difference between
patients with NA therapy for less than 12 months and those
with NA therapy for more than 12 months (p Z 0.003).
There was also a significant difference between patients
without antiviral therapy and those with more than 12
months of treatment (p Z 0.03). Patients with NA therapy
of more than 12 months had significantly lower LSM values
(Fig. 3).Discussion
Systemic reviews and meta-analyses demonstrated that
LSM performed well for the diagnosis of hepatic fibrosis or
cirrhosis [4e7]. Although there are various cutoff values in
the prediction of cirrhosis in different populations studied,
the diagnosis of cirrhosis was likely when the LSM value was
above 12.5 or 13 kPa [6,17]. In the present study with
regard to compensated cirrhotic patients, the median LSM
value was 9.6 kPa for those with persistent normal ALT level
during the 2-year period. For chronic HCV patients with SVR
after antiviral therapy, the median LSM value was 11.2 kPa.
The median LSM value was 10.6 kPa for chronic HBV
patients after NA therapy for more than 12 months. Despite
the diagnosis of compensated cirrhosis, patients with long-
term biochemical resolution or effective antiviral therapy
had LSM values lower than the cutoff values proposed.
Previous studies have suggested that LSM has been
shown to increase with acute biochemical flares of hepatitis
[10e12]. LSM value was also higher in chronic hepatitis
patients with abnormal ALT levels without acute flare-up
than those with normal ALT levels. In patients with
biochemical or histological activities, high LSM values may
be related to hepatocyte swelling, tissue necrosis, or infil-
tration of inflammatory cells. These studies demonstrated
that LSM increased with elevated hepatitis activities. In the
present study with respect to cirrhotic patients with 2-year
follow-up of serum ALT level, LSM was influenced by the
patterns of ALT level changes. LSM value was affected not
only by the hepatitis activity at the time of LSM, but also by
the patterns of hepatitis activity change in long-term
follow-up. Therefore, it would be necessary to consider
the long-term patterns of ALT level change in the inter-
pretation of LSM values in the diagnosis of hepatic cirrhosis.
Table 3 Demographics and clinical characteristics of patients with chronic HCV infection stratified into without antiviral
therapy, non-sustained viral response (NSVR), and sustained viral response (SVR) groups by antiviral treatment and its effect.
Groups Total
n Z 47 (%)
No therapy
n Z 21 (%)
NSVR
n Z 12 (%)
SVR
n Z 14 (%)
p
Age (y) 62.0  9.9 63.3  10.4 58.7  10.7 62.9  8.2 0.417
Sex
Male 21 (44.7) 9 (42.9) 5 (41.7) 7 (50.0) 0.890
Female 26 (55.3) 12 (57.1) 7 (58.3) 7 (50.0)
BMI (kg/m2) 26.6  3.9 25.6  3.1 28.7  5.6 26.1  2.7 0.078
Platelet count (109/L)
<150 35 (74.5) 18 (85.7) 10 (83.3) 7 (50.0) 0.061
S150 12 (25.5) 3 (14.3) 2 (16.7) 7 (50.0)
Prothrombin time (INR) 1.06  0.07 1.06  0.07 1.10  0.07 1.03  0.05 0.034
AST (UI/L) 59.7  43.7 55.8  23.9 99.4  63.5 31.5  13.4 <0.001
ALT (UI/L) 60.2  53.4 55.9  29.1 104.6  81.8 28.5  13.7 0.001
Albumin (g/dL) 4.1  0.4 4.0  0.4 3.9  0.4 4.4  0.2 <0.001
Total bilirubin (mg/dL) 1.2  0.5 1.2  0.6 1.4  0.6 0.9  0.3 0.052
Liver stiffness (range, kPa) 16.6 (3.9e61.5) 16.6 (8.1e61.5) 22.9 (11.1e37.4) 11.2 (3.9e27.0) 0.003
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; BMI Z body mass index; INR Z international normalized ratio.
Figure 2. Liver stiffness values stratified by treatment and
its effect in cirrhotic patients with chronic hepatitis C. For
patients with chronic hepatitis C virus infection, the median
liver stiffness measurement (LSM) value was 16.6 kPa (range
8.1e61.5 kPa) in patients without antiviral therapy, 11.2 kPa
(range 3.9e27.0 kPa) in patients with sustained virological
response (SVR), and 22.9 kPa (range 11.1e37.4 kPa) in patients
with non-sustained virological response (NSVR).
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the diagnosis of cirrhosis have been proposed due to
differences in the studied populations and etiologies [17].
In our previous study, the optimum cutoff value was 12 kPa
for LSM in the diagnosis of cirrhosis, with a sensitivity of
79%, a specificity of 85%, and a negative predictive value of
94% [18]. However, these studies failed to take into account
the effect of biochemical activities of the patients studied.
In this study, we found that in cirrhotic patients with
persistent normal or episodically elevated ALT levels, the
LSM values were lower than the proposed cutoff level for
diagnosing cirrhosis. Their low LSM values might be false
negative results for the diagnosis of cirrhosis [19]. There
were several ways to increase the diagnostic accuracy of
cirrhosis, including using different cutoff values in different
ALT levels and combination with other noninvasive models
[18,20e23]. Chan et al. [20] proposed an ALT-based algo-
rithm for patients with chronic hepatitis B, and their test
optimal cutoff values ranged from 8.4 to 12.0 kPa for
cirrhosis. Kim et al. [21] showed that a combination of LSM
and the age/spleen/platelet ratio index achieved good
accuracy at predicting cirrhosis regardless of ALT level. The
combination of LSM with fibrosis markers or with US study
comprised the other options [18,22,23]. Alternatively, now
that LSM values parallel ALT levels [10], a correction
formula for LSM in diagnosis of cirrhosis might be developed
in a future study.
Antiviral treatment was recommended for select
patients with chronic viral hepatitis to improve prognosis
and increase survival [1,2]. The primary goals of treatment
were SVR for chronic HCV infection and long-term
suppression of viral replication for chronic HBV infection.
These will achieve regression of hepatitis activity and
fibrosis in long-term follow-up. LSM has been demonstrated
to be useful as a noninvasive method for monitoring the
effect of antiviral treatment [13,14,24e26]. With effective
antiviral therapy for chronic HBV infection, improvement of
Figure 3. Liver stiffness values stratified by treatment in
cirrhotic patients with chronic hepatitis B. For patients with
chronic hepatitis B virus infection, the median liver stiffness
measurement (LSM) value was 11.8 kPa (range 5.1e46.6 kPa) in
patients without antiviral therapy, 16.9 kPa (range 4.2e48 kPa)
in patients with nucleos(t)ide analogue (NA) therapy less than
12 months, and 10.6 kPa (range 4.3e46.4 kPa) in patients with
therapy of more than 12 months.
Table 4 Demographics and clinical characteristics of chronic HBV infection stratified into without oral nucleoside/nucleotide
analogs (NA) antiviral therapy, with therapy groups of less than 12-month and more than 12-month treatment modalities.
Groups Total
n Z 89 (%)
No NA therapy
n Z 43 (%)
NA <12 Ms
n Z 13 (%)
NA S12 Ms
n Z 33 (%)
p
Age (y) 54.9  10.6 53.0  11.1 57.3  11.5 56.6  9.3 0.231
Sex
Male 55 (61.8) 25 (58.1) 9 (69.2) 21 (63.6) 0.765
Female 34 (38.2) 18 (41.9) 4 (30.8) 12 (36.4)
BMI (kg/m2) 25.1  3.5 25.3  3.5 26.3  4.3 24.4  2.9 0.195
Platelet count (109/L)
<150 61 (68.5) 29 (67.4) 12 (92.3) 20 (60.6) 0.109
S150 28 (31.5) 14 (32.6) 1 (7.7) 13 (39.4)
Prothrombin time (INR) 1.06  0.06 1.06  0.06 1.06  0.06 1.05  0.06 0.560
AST (UI/L) 43.2  32.5 49.3  41.6 49.9  21.3 32.6  16.7 0.059
ALT (UI/L) 46.5  51.1 58.1  68.0 45.5  27.3 31.9  20.7 0.085
Albumin (g/dL) 4.2  0.4 4.2  0.3 4.1  0.3 4.3  0.5 0.548
Total bilirubin (mg/dL) 1.1  0.5 1.0  0.4 1.2  0.5 1.2  0.6 0.156
Liver stiffness (range, kPa) 11.6 (4.2e48) 11.8 (5.1e46.6) 16.9 (4.2e48) 10.6 (4.3e46.4) 0.009
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; BMI Z body mass index; INR Z international normalized ratio.
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regression of fibrosis in limited patient numbers [14,24]. In
our study with respect to patients in compensated cirrhosis,
the median LSM value was 11.2 kPa in the SVR group for
chronic HCV infection and 10.6 kPa in the long-term NA
therapy group for chronic HBV infection, which were lower
than the values obtained for those without or with inef-
fective antiviral therapy. In clinical practice, these would
cause false negative results for the diagnosis of cirrhosis.
Thus, the effect of antiviral therapy should be assessed in
the interpretation of LSM value for the diagnosis of
cirrhosis.
Low liver stiffness in cirrhosis after effective antiviral
therapy might be related to the regression of hepatitis
activity, fibrosis, or both. Short-term effective antiviral
therapy would ameliorate hepatic inflammation and
decrease liver stiffness. Long-term remission, however, is
necessary for fibrosis regression. For patients with chronic
HCV infection in SVR, a previous longitudinal study
demonstrated that LSM decreased slowly for patients in
long-term remission [13]. In our study, the interval between
SVR and LSM was long enough for fibrosis regression for
patients with chronic HCV infection. The lower LSM value in
patients with chronic HCV infection might reflect the
regression of fibrosis. Since long-term NA therapy for
chronic HBV infection may be required before fibrosis
regression for patients with remission [27], lower stiffness
in patients with chronic HBV infection may be due to
regression of hepatic inflammation and fibrosis regression in
this study. Forty-three patients had chronic HBV without
antiviral therapy in our study. There was a similar ALT level
between these patients and patients with NA therapy for
more than 12 months. However, a significantly higher LSM
value was noted in those without NA therapy. The effect of
long-term NA therapy in decreasing liver stiffness may not
only be by normalization of ALT level but also by suppres-
sion of HBV replication. Therefore, for patients with HBV-
LSM in cirrhosis d Implications of DA and TX 647related cirrhosis, even with low ALT level and low HBV
replication, long-term HBV suppression may prove neces-
sary [1].
Despite all patients in this study being diagnosed with
cirrhosis and 55.2% with ultrasonographically determined
portal hypertension, there were patients with regression of
fibrosis and even reversal of cirrhosis after long-term
normalization of hepatitis activity and effective antiviral
therapy. The discrepancy between US and LSM in the
diagnosis of cirrhosis was due to the different criteria set in
cirrhosis diagnosis. While LSM value was based on fibrosis
stage, US diagnosis of cirrhosis was based on structural
change induced by fibrosis, especially liver surface nod-
ularity [18,28]. Compared to fibrosis regression, structural
changes might take longer and will improve only in patients
with fibrosis amelioration. This might explain why LSM
values declined and US scores did not improve in patients
after effective antiviral therapy. Whether cirrhosis
regressed to mild or moderate fibrosis stages in these
patients, however, warrants further confirmation in future
histological study.Conclusion
In summary, there is a lower LSM value in compensated
cirrhotic patients with long-term persistent or episodic
hepatitis activity. For patients with chronic HCV- or HBV-
related cirrhosis, there was a low liver stiffness value in
those with HCV eradication and long-term HBV suppression
after antiviral therapy. These should be taken into account
in the interpretation of LSM value for the diagnosis of
hepatic cirrhosis.Acknowledgments
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